Teijin begins construction on $20 million site in western Japan

Japanese pharma company Teijin (TYO: 3104) is to build a Technology Integrated Pharmaceutics Center to leverage the group’s total resources for development of integrated pharmaceuticals, such as a fibrin sheet offering hemostatic and tissue-sealing properties for surgical operations.

The two-story building is to be fitted with Good Manufacturing Practice zones, manufacturing and testing equipment and unique research and development facilities for pharma material integration. The facility measures 2,3000 square meters in floor space and will be located in the Pharmaceutical Products Research Laboratories of Teijin’s Iwakuni factory in western Japan. Construction is to begin this month and will be finished in the fall of 2015, at a cost of around 2 billion yen ($20.8 million).

The group is restructuring its tech portfolio under a medium- to long-term management plan aimed at creating new health care business by overlapping the groups material and health care domains. The Center will consolidate systems for research and development functions for integrative products as well as facilitate the manufacture of investigational drugs.